LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Home・Список акций・Design Therapeutics Inc

Design Therapeutics Inc

Закрыт

9.28 -5.5

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

9.1

Макс.

9.83

Ключевые показатели
By Trading Economics
Доход	2.1M -17M
Рентабельность продаж	-2,321.599
Сотрудники	55
EBITDA	4.7M -17M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+41.99% upside

Рыночная статистика
By TradingEconomics
Рыночная капитализация	189M 562M
Предыдущая цена открытия	14.78
Предыдущая цена закрытия	9.28

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

3.26 / 3.63 Поддержка и Сопротивление

Design Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

9 дек. 2025 г., 22:13 UTC

Отчет

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 дек. 2025 г., 21:40 UTC

Отчет

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 дек. 2025 г., 18:51 UTC

Приобретения, слияния, поглощения

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 дек. 2025 г., 16:57 UTC

Главные движущие силы рынка

Clear Secure Rises on Medicare Identity Verification Contract

9 дек. 2025 г., 23:46 UTC

Обсуждения рынка

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 дек. 2025 г., 23:46 UTC

Приобретения, слияния, поглощения

Legend Holdings Stake in Lenovo Now at 32.34%

9 дек. 2025 г., 23:45 UTC

Приобретения, слияния, поглощения

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 дек. 2025 г., 23:44 UTC

Приобретения, слияния, поглощения

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 дек. 2025 г., 23:43 UTC

Приобретения, слияния, поглощения

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 дек. 2025 г., 23:43 UTC

Приобретения, слияния, поглощения

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 дек. 2025 г., 23:35 UTC

Обсуждения рынка

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 дек. 2025 г., 22:42 UTC

Отчет

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Tech, Media & Telecom Roundup: Market Talk

9 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

9 дек. 2025 г., 21:48 UTC

Обсуждения рынка

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 дек. 2025 г., 21:36 UTC

Отчет

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 дек. 2025 г., 21:36 UTC

Отчет

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 дек. 2025 г., 21:36 UTC

Отчет

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 дек. 2025 г., 21:36 UTC

Отчет

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 дек. 2025 г., 21:36 UTC

Отчет

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 дек. 2025 г., 20:28 UTC

Обсуждения рынка

Oil Futures Decline for Second Straight Session -- Market Talk

9 дек. 2025 г., 20:27 UTC

Приобретения, слияния, поглощения

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 дек. 2025 г., 20:27 UTC

Приобретения, слияния, поглощения

Teck Reports Voting Results From Special Meeting of Hldrs

9 дек. 2025 г., 20:26 UTC

Обсуждения рынка

Приобретения, слияния, поглощения

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 дек. 2025 г., 20:21 UTC

Обсуждения рынка

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 дек. 2025 г., 19:52 UTC

Отчет

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 дек. 2025 г., 19:17 UTC

Отчет

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 дек. 2025 г., 17:20 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

9 дек. 2025 г., 17:15 UTC

Обсуждения рынка

Global Commodities Roundup: Market Talk

9 дек. 2025 г., 17:11 UTC

Отчет

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Сравнение c конкурентами

Изменение цены

Design Therapeutics Inc Прогноз

Целевая цена

By TipRanks

41.99% рост

Прогноз на 12 месяцев

Средняя 14 USD 41.99%

Максимум 15 USD

Минимум 13 USD

Основано на мнении 3 аналитиков Wall Street, спрогнозировавших целевые цены для Design Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

3 ratings

Покупка

Удержание

Продажа

Основано на мнении 3 аналитиков, присваивавших рейтинги акциям Design Therapeutics Inc – Данные за последние 3 месяца.

Техническая оценка

By Trading Central

3.26 / 3.63Поддержка и Сопротивление

Recent bearish events outweigh bullish events.

All events are bearish.

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.